Zobrazeno 1 - 10
of 21
pro vyhledávání: '"G. A. Curt"'
Autor:
G. A. Curt
Publikováno v:
The Oncologist. 5:9-12
Autor:
G A, Curt
Publikováno v:
Recenti progressi in medicina. 92(6)
As oncologists have become more effective in alleviating pain, nausea and depression, fatigue has emerged as the most important symptom suffered by cancer patients. Indeed, the current literature suggests that fatigue is currently the most important
Autor:
N J, Vogelzang, W, Breitbart, D, Cella, G A, Curt, J E, Groopman, S J, Horning, L M, Itri, D H, Johnson, S L, Scherr, R K, Portenoy
Publikováno v:
Seminars in hematology. 34(3 Suppl 2)
Although fatigue is the most common symptom reported by cancer patients and has serious adverse effects on quality of life, it remains poorly understood. A survey was designed to characterize the epidemiology of cancer-related fatigue from the perspe
Autor:
P. D. Porter, G. A. Curt, B. J. Miller, J. A. Hautala, James H. Doroshow, D. Shoemaker, Sheila A. Prindiville
Publikováno v:
Journal of Clinical Oncology. 29:e16600-e16600
e16600 Background: Negotiation of clinical trial agreements (CTAs) between industry and academic medical centers is one of the barriers to timely initiation of cancer clinical trials. It is perceiv...
Publikováno v:
JAMA: The Journal of the American Medical Association. 255:505-507
Immunoaugmentative therapy is an unproved cancer treatment that until recently was offered to patients by zoologist Lawrence Burton, PhD, at a facility in Freeport, Bahamas. The therapy consists of serum measurements of certain "immune deficiencies"
Publikováno v:
British Journal of Cancer
Two cell lines, one sensitive and one resistant to the cytotoxic effects of cytosine arabinoside (AraC) were studied in vitro as a drug-resistance model. The sensitivity of these cell lines, to the effects of free and liposomally trapped AraC and Ara
Publikováno v:
Cancer treatment reports. 69(6)
A competitive protein-binding assay has been developed for trimetrexate (TMTX) based on the tight binding of this drug to human dihydrofolate reductase (tetrahydrofolate dehydrogenase). In this assay, TMTX competes with 3H-methotrexate for binding to
Autor:
G A, Curt
Publikováno v:
The New England journal of medicine. 311(13)
Publikováno v:
Cancer treatment reports. 67(10)
Data are presented from two cell culture systems which support the notion that a multi-drug-resistant phenotype occurs in human tumor cell populations. Human small cell lung cancer cell lines derived from patients in relapse following intensive combi
Autor:
G A, Curt, J A, Kelley, R L, Fine, P N, Huguenin, J S, Roth, G, Batist, J, Jenkins, J M, Collins
Publikováno v:
Cancer research. 45(7)
5,6-Dihydro-5-azacytidine (DHAC; NSC 264880) is an analogue of 5-azacytidine that does not possess the hydrolytically unstable 5,6-imino bond of the parent compound. Thus, unlike 5-azacytidine, DHAC is stable in aqueous solution and may be administer